NX-5948

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

Sorting 7 by

Memorial Sloan Kettering Cancer Center
New York, NY
Fully Open
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Bergen
Montvale, NJ
Limited Activities
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Basking Ridge
Basking Ridge, NJ
Limited Activities
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Commack
Commack, NY
Limited Activities
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Monmouth
Middletown, NJ
Limited Activities
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Nassau
Uniondale, NY
Limited Activities
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Westchester
West Harrison, NY
Limited Activities
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.